MedTrace Logo

Efficacy and Tolerability of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients Older Than 18 Years

NCT00994760 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 131

Last updated 2012-09-27

Study results available
· View outcomes & findings →

Summary

The aim of the study was to evaluate the safety and efficacy of intranasal fentanyl spray in cancer patients over four weeks, especially during cancer-related breakthrough pain (BTP) attacks. The fentanyl spray was applied into the nose by a metered-spray device. The study was to provide further data on pharmacoeconomic efficiency of intranasal fentanyl spray.

Conditions

Interventions

DRUG

Instanyl (Intranasal Fentanyl)

This was an observational study. Therefore, the physician decided about dosage according to individual needs.

Sponsors & Collaborators

Principal Investigators

  • Dr. Thomas D. Bethke, PhD; MD · Nycomed Deutschland GmbH, 78467 Konstanz, Germany

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-09-30
Completion
2010-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00994760 on ClinicalTrials.gov